Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

NCT07172464 is registered in ClinicalTrials.gov with Recross Cardio, Inc. as lead sponsor.

NCT NCT07172464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07172464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
Lead sponsor
Recross Cardio, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
October 9, 2025
Completion date
February 28, 2031
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cryptogenic stroke, patent foramen ovale, pfo, pfo - patent foramen ovale, pfo-associated stroke